what are the newer options for patients who fail first- and second-generation tki therapies?
Published 8 years ago • 42 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
1:22
what are the major reasons why patients fail to respond to tki therapies?
-
1:41
efficacy of dual egfr and met inhibition in nsclc post egfr tki failure
-
5:57
adverse events of second-generation tkis used in treating cml
-
7:45
the feasibility of tki discontinuation
-
3:56
how do we recognize treatment failure or treatment resistance?
-
1:00
why is adherence to tki therapies so important?
-
5:34
second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia
-
4:36
the kynurenine/tryptophan ratio: an integrated measure of many pro- and anti-inflammatory factors
-
9:08
selecting a tyrosine kinase inhibitor in chronic myeloid leukemia case study
-
2:54
protein kinases: cell signaling and phosphorylation
-
3:12
second-generation tyrosine kinase inhibitors for chronic myeloid leukemia
-
8:40
what are the key challenges in the treatment of heart failure?
-
5:21
case 2: choosing the right treatment option
-
2:31
common obstacles that hinder adoption of new technologies in healthcare
-
18:33
esc guidelines: did we miss something in hf (english version)
-
6:45
anti-pd1 or tyrosine kinase inhibitors?
-
4:09
tyrosine kinase inhibitors in egfr-mutant nsclc: when and who?
-
10:47
the importance of monitoring patients on tkis
-
1:02
what are mutational studies and how do i interpret them?
-
4:33
optimizing discontinuation of tyrosine kinase inhibitor treatment for chronic myeloid leukemia
-
0:47
what are my treatment options?